For the quarter ending 2025-09-30, MBRX had -$854K decrease in cash & cash equivalents over the period. -$7,223K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -35,036 | -14,076 |
| Depreciation and amortization | 22 | 59 |
| Stock-based compensation | 303 | 902 |
| Change in fair value of warrant liability | 17,632 | -18,663 |
| Loss on issuance of warrant liabilities | -12,812 | -18,150 |
| Operating lease, net | -3 | 116 |
| Transaction costs allocated to warrant liabilities | -1,258 | 2,995 |
| Prepaid expenses and other assets | -337 | 1,503 |
| Accounts payable | -1,483 | 1,526 |
| Accrued expenses and other current liabilities | -549 | 348 |
| Net cash used in operating activities | -7,223 | -10,146 |
| Purchase of fixed assets | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from exercise of warrants | 1,111 | 10 |
| Payment of tax liability for vested restricted stock units | 0 | 0 |
| Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs | 5,264 | 13,412 |
| Net cash provided by financing activities | 6,375 | 13,422 |
| Effect of exchange rate changes on cash and cash equivalents | -6 | 3 |
| Net increase (decrease) in cash and cash equivalents | -854 | 3,279 |
| Cash and cash equivalents at beginning of period | 4,278 | - |
| Cash and cash equivalents at end of period | 6,703 | - |
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)